Craniometrix vs Moderna

Side-by-side comparison of AI visibility scores, market position, and capabilities

Moderna leads in AI visibility (90 vs 36)
Craniometrix logo

Craniometrix

EmergingHealthcare

General

SF dementia care coordination platform with Johns Hopkins MIND at Home partnership; YC $6.5M with $1.9M revenue connecting patients and caregivers through virtual care navigation for Alzheimer's management.

AI VisibilityBeta
Overall Score
D36
Category Rank
#503 of 596
AI Consensus
85%
Trend
stable
Per Platform
ChatGPT
41
Perplexity
36
Gemini
36

About

Craniometrix is a San Francisco-based digital health company providing virtual dementia care coordination — connecting dementia patients, family caregivers, and healthcare providers through a telemedicine platform that delivers cognitive assessment, care planning, caregiver education, and ongoing care management for Alzheimer's and related dementia conditions. Founded by CEO Nikhil Patel and backed by Y Combinator with $6-6.5 million raised from Y Combinator, Quiet Capital, and Defy.vc, Craniometrix generated $1.9 million in revenue in 2024 and partners with the Johns Hopkins MIND at Home program — a validated community-based dementia care model developed by Johns Hopkins University School of Medicine.

Full profile
Moderna logo

Moderna

LeaderHealthcare Tech

Enterprise

mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.

AI VisibilityBeta
Overall Score
A90
Category Rank
#2 of 596
AI Consensus
83%
Trend
stable
Per Platform
ChatGPT
92
Perplexity
93
Gemini
89

About

Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.

Full profile

AI Visibility Head-to-Head

36
Overall Score
90
#503
Category Rank
#2
85
AI Consensus
83
stable
Trend
stable
41
ChatGPT
92
36
Perplexity
93
36
Gemini
89
41
Claude
96
39
Grok
95

Key Details

Category
General
Enterprise
Tier
Emerging
Leader
Entity Type
brand
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.